Wenzhou Medical University

Corxel Pharmaceuticals and LENZ Therapeutics announced positive phase 3 JX07001 trial results for LNZ100, showing significant improvements in near vision and maintenance of distance vision in Chinese presbyopic patients. LNZ100 demonstrated rapid onset, long duration, and was well-tolerated, with no serious adverse events. The study highlights LNZ100's potential as a global therapy for presbyopia.

Corxel Pharmaceuticals and LENZ Therapeutics announced positive phase 3 JX07001 trial results for LNZ100, showing significant improvements in near vision with no loss of distance vision in Chinese presbyopic patients. LNZ100 demonstrated rapid onset, long duration, and was well-tolerated, with no serious adverse events. The study highlights LNZ100's potential as a global therapy for presbyopia.

CORXEL and LENZ Therapeutics announce positive Phase 3 data for LNZ100 in China, showing 74% of participants achieved three-lines or greater improvement at 3 hours post-treatment for presbyopia, with rapid onset (69% at 30 minutes) and sustained efficacy (30% at 10 hours). LNZ100 was well-tolerated, and the FDA has accepted the New Drug Application for the US market.